Podcasts

Misha Rosenbach, MD, director of the sarcoidosis and granulomatous clinic at the Perelman School of Medicine, reviews how to diagnose and manage cutaneous manifestations of sarcoidosis.

In this podcast, Ana-Maria Orbai, MD, MHS, talks about the interchangeability between the HAQ-DI and PROMIS-PF in the measurement of minimal disease activity among patients with psoriatic arthritis and how it may influence your practice.

Lawrence Green, MD, discusses with Kristi Hawley, DO, strategies for selecting treatment options for patients with obesity and psoriasis, as well as patients at risk for cardiometabolic disease.

He discusses some of the difficulties rheumatologists encounter when diagnosing psoriatic arthritis, and key indicators of the disease.

He talks about the challenges of treating progressive psoriatic arthritis, why certain patients progress to more severe disease, and how to change medication when needed.

Adam Cheifetz, MD, a cochair of the virtual Interdisciplinary Autoimmune Summit (IAS) 2020, gives an overview of his presentation on how proactive and reactive therapeutic drug monitoring differ and how the proactive approach can significantly benefit patients with autoimmune diseases.

She discusses her research on assays for measuring drug concentrations and anti-drug antibodies, as well as algorithmic approaches to proactive therapeutic drug monitoring and how they help patients with IBD achieve and maintain remission.

In this podcast, Parambir Dulai, MD, discusses his recent research on treating inflammatory bowel disease to achieve endoscopic remission, through the use of a treat-to-target approach using algorithmic treatment adjustments.

In this podcast, gastroenterologist David Hudesman, MD, and rheumatologist José Scher, MD, discuss their prospective case series involving patients with known immune-mediated inflammatory diseases who were receiving anticytokine biologics, other immunomodulatory therapies, or both when confirmed or highly suspected symptomatic COVID-19 developed.

He talks about his study that evaluated the influence of distinct domains of rheumatoid arthritis disease activity, functional limitation, mood disturbance, as well as RA-specific knowledge and patients’ beliefs about medications on treatment adherence.